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Abstract 
Introduction: Preclinical studies suggest a link between cAMP/PKA signalling, 
phosphodiesterase 4 (PDE4) expression and excessive daytime sleepiness (EDS). Here, we 
investigated in vivo the association between PDE4 expression and EDS in Parkinson’s disease 
(PD) patients using [11C]rolipram PET and MR imaging.  
Methods: Eighteen participants, 12 PD and 6 healthy controls, underwent one [11C]rolipram 
PET and a multi-modal MRI scan. Probabilistic tractography was performed on subjects’ 
diffusion data to functionally parcellate the striatum according with projections to limbic 
cortical areas. The severity of EDS was assessed using the Epworth Sleepiness Scale (ESS). 
To assess PDE4 expression in PD patients with EDS, the PD cohort was divided according to 
the presence (n=5) or absence (n=7) of EDS, defined using validated cut-off of score ≥10 on 
the ESS as score ≥10 on the ESS. 
Results: PD patients with EDS showed significantly increased [11C]rolipram volume of 
distribution (VT) in the caudate (P=0.029), hypothalamus (P=0.013), hippocampus (P=0.036) 
and limbic striatum (P=0.030) compared to patients without EDS. Furthermore, higher ESS 
scores correlated with increased [11C]rolipram VT in the caudate (r=0.77; P=0.003), 
hypothalamus (r=0.84; P=0.001), hippocampus (r=0.81; P=0.001) and limbic subdivisions of 
the striatum (r=0.80; P=0.003). 
Conclusion: Our findings translate into humans preclinical data indicating that EDS is 
associated with elevated PDE4 in regions regulating sleep. The severity of EDS in PD was 
associated with elevated PDE4 expression; thus, suggesting a role of PDE4 in the 
pathophysiology of EDS in PD.   
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Introduction  
Excessive daytime sleepiness (EDS) is one of the most common sleep disturbances in 
Parkinson’s disease (PD) affecting around 50% of patients [1]. EDS is characterised by a 
tendency of rapid sleep onset during waking hours without prior drowsiness [2] and has been 
linked to deficits in attention and memory [3]. Positron emission tomography (PET) and single-
photon emission computed tomography (SPECT) studies have shown that dopaminergic and 
serotonergic dysfunction may contribute to the development of EDS in PD [4-6]. However, the 
mechanisms underlying pathophysiology of daytime sleepiness in PD remain unclear.  
Preclinical studies have provided evidence that phosphodiesterase 4 (PDE4) plays a role in 
daytime sleepiness [7-10]. PDE4 is an intracellular enzyme which hydrolyses cyclic adenosine 
monophosphate (cAMP), thus regulating signalling cascade including cAMP-protein kinase A 
(PKA)-cAMP response binding protein (CREB) [11]. PDE4 is highly expressed in the striatum, 
thalamus, cerebellum, hippocampus and cortex [12]. A genome-wide association study of sleep 
and circadian phenotypes identified eight single nucleotide polymorphism (SNP) were 
associated with sleep phenotypes [10]. The SNP rs1823068, located in an intron of the PDE4 
gene on chromosome 5, had the strongest association with increased daytime sleepiness [10]. 
Elevated cAMP/PKA signalling has recently been reported in the brain of an animal model of 
Huntington’s disease (HD) animal models with sleep deficits [8]. Moreover, selective PDE4 
inhibitors promote wakefulness [7]. Sleep deprivation has also been shown to increase PDE4 
protein levels and activity in the hippocampus, subsequently reducing cAMP signalling and 
impairing hippocampal cAMP/PKA-dependent forms of synaptic plasticity [9]. 
A recent PET study showed altered PDE4 expression in Parkinson’s disease patients [13]. 
Therefore, given the preclinical evidence for the role of PDE4 in sleep-related problems we 
aimed to investigate whether changes in PDE4 levels could be related to the development of 
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EDS. We hypothesized that elevated PDE4 levels, in brain regions regulating the sleep-wake 
cycle, could play a role in the pathophysiology of EDS in PD. Here, we investigated in vivo the 
expression of PDE4 in PD patients with and without EDS using multi-modal magnetic 
resonance imaging (MRI) and PET with [11C]rolipram, a selective PDE4 radioligand [14, 15].   
 
Methods  
Participants 
We recruited eighteen subjects, twelve patients with idiopathic PD and six age- and gender-
matched healthy controls with no history of any psychiatric or neurological disorders and not 
on treatment with medications. PD patients had no history of other neurological or psychiatric 
disorders, and were not under treatment with substances with known actions in PDEs. All PD 
patients were on stable dopaminergic treatment (levodopa and/or dopamine agonists) for at 
least six months at the time of study enrolment. Daily dopamine agonist equivalent dose 
(LEDDA) and daily levodopa equivalent dose (LEDL-DOPA) unit calculations were based on 
theoretical equivalence to levodopa as described previously [16]. Participants underwent 
clinical assessments to evaluate motor, cognitive and psychiatric symptoms severity (Table 1). 
Motor symptom severity was assessed with the Unified Parkinson’s Disease Rating Scale part-
III (UPDRS-III) and staged with Hoehn & Yahr (H&Y) scale. Motor assessments were 
performed OFF medication after overnight withdrawal of patient’s dopaminergic medications 
and following a challenge with levodopa 250/carbidopa 25, with an observational ON-
medication period of 150 min. Quality of life was measured with the patient self-reported 39-
item Parkinson's disease Questionnaire (PDQ-39). Non-motor symptoms were assessed using 
UPDRS part-I (UPDRS-I), Non-Motor symptom scale (NMSS), Parkinson’s disease sleep 
scale (PDSS) and Epworth Sleepiness Scale (ESS). Depression was assessed using the Beck 
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Depression Inventory-II (BDI-II) and Hamilton Depression Rating Scale (HAM-D). General 
cognitive status was assessed using the Mini Mental Status Examination (MMSE) and 
Montreal Cognitive Assessment (MoCA).  
Severity of EDS was assessed using the Epworth Sleepiness Scale (ESS); higher ESS scores 
indicate greater daytime sleepiness. To assess PDE4 expression in PD patients with EDS, the 
PD cohort was divided according to the presence (n=5) or absence (n=7) of EDS, defined using 
validated cut-off of score ≥10 on the ESS as score ≥10 on the ESS [17] (Table 1).  
All participants screened successfully to undertake PET and MRI scanning under standard 
criteria (http://www.mrisafety.com; https://www.gov.uk/government/publications/arsac-
notes-for-guidance). Written informed consent was obtained from all study participants in 
accordance with the Declaration of Helsinki. The study was approved by the institutional 
review boards and the research ethics committee.  
Scanning procedures 
PET and MR imaging was performed at Invicro, London, UK. Patients stopped all 
dopaminergic medication and withheld from consumption of caffeinate beverages for 12 hours 
before the scan. Long acting dopaminergic medications were withdrawn for 72 hours prior to 
the PET scan. MRI scans were acquired with a 32-channel head coil on a Siemens Magnetom 
Verio 3-T MRI scanner and included: T1-weighted magnetization prepared rapid acquisition 
with gradient echo sequence (MPRAGE; time repetition (TR) = 2300ms, time echo (TE) = 
2.98ms, flip angle of 9°, time to inversion (T1) = 900ms, matrix = 240 x 256) for co-registration 
with the PET images; fast grey matter T1 inversion recovery (FGATIR; TR = 6000ms, TE = 
2.96ms, flip angle of 8°, T1 = 409ms, matrix = 240 x 256) for manual delineation of subcortical 
regions of interest; and diffusion-weighted data (DTI) for probabilistic tractography and 
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connectivity-based parcellation of the striatum. All sequences used a 1 mm3 voxel size, 
anteroposterior phase encoding direction, and a symmetric echo. 
Diffusion-weighted data were acquired for performing probabilistic tractography and 
connectivity-based parcellation of the striatum using echo planar imaging (EPI; TR = 8000ms, 
TE = 96ms, flip angle of 90° and voxel size of 2 x 2 x 2 mm3). The diffusion weighting as 
isotropically distributed along the 32 directions (b-value = 1000 s/mm2), and a non-diffusion-
weighted imaging (b0) was acquired at the beginning of each scan. To minimize EPI geometric 
distortions, two image sets were acquired with the phase-encoded direction reversed, ‘blip-up’ 
and ‘blip-down’, allowing for the calculation of a corrected image.  
[11C]Rolipram, PET scans were obtained on a Biograph Hi-Rez 6 PET-CT scanner (Siemens) 
one hour following a standard levodopa 250/carbidopa 25 dose. A mean dose of 306.0 MBq 
[11C]rolipram (SD: ± 49.0) [mean mass injected: 2.8 ug (SD: ± 1.6)] was intravenously 
administered as a slow bolus injection over 20s. Dynamic emission data were acquired 
continuously for 90 minutes. The dynamic images were reconstructed into 26 frames using a 
filter back projection algorithm (direction inversion Fourier transform) with a 128 matric, zoom 
of 2.6 producing images with isotropic voxel size 2 x 2 x 2 mm3, and smoothed with a transaxial 
Guassian filter of 5mm. Blood sampling was performed through an arterial line inserted in the 
radial artery to generate arterial plasma input data. For the initial 15 minutes radioactivity levels 
in blood was continuously measured through an automatic blood sampling system at 5ml/min, 
followed by samples at 5, 10, 15, 15, 20, 25, 30, 40, 50, 60, 70, 80 and 90 min during the scan.  
[11C]rolipram parent fraction over the course of the PET scan was determined by HPLC using 
the Hilton column switching method [18].  
Imaging data analysis  
MRI-based volumetric analysis  
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Grey matter atrophy has been reported in PD patients with EDS compared to those with EDS 
[19]. Therefore, we investigated volumetric changes in cortical and subcortical nuclei regions 
between groups of PD patients using the FreeSurfer’s image analysis suite (version 5.3.0 
http://surfer.nmr.mgh.harvard.edu) to process individual MRI scans for deriving measures of 
cortical thickness and subcortical nuclei volumes. Adjustments for intracranial volume were 
calculated for each region-of-interest (ROI) using validated methods within the FreeSurfer 
toolkit. We also carried out volumetric analysis, on each subjects volumetric T1-weighted MRI, 
for bilateral manually delineated ROIs and DTI connectivity-based ROIs.  
[11C]rolipram PET data analysis  
Image processing and kinetic modelling was carried out using the Molecular Imaging and 
Kinetic Analysis Toolbox software package (MIAKATTM: www.miakat.org), implemented in 
MATLAB (The Mathworks, Natick, MA, USA). MIAKATTM combines in-house code with 
wrappers for FMRIB Software Library (FSL, University of Oxford) and Statistical Parametric 
Mapping (SPM, Wellcome Trust Centre for Neuroimaging). For [11C]rolipram data, parent in 
plasma input function were generated using the continuous and discrete blood samples. The 
Hill model was used to model the parent fraction data [20]. Regional time-activity data was 
derived from dynamic PET data and volume of distribution (VT) values estimated using the 2-
Tissue compartmental model. Parametric [11C]rolipram VT images were generated with the 
Logan plot [21].  
Region-of-interest analysis 
To investigate whether changes in PDE4 levels could be related to the development of EDS, 
we quantified PDE4 levels, in brain regions involved in the limbic system and in regulating the 
sleep-wake cycle. Parametric PET images were co-registered and resliced to corresponding 
FGATIR MR images in SPM12 software package implemented in Matlab 2015a. The 
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anatomical CIC atlas version 2.0 [22] was used to define allo-cortical ROIs involved in the 
limbic system including the amygdala, hippocampus, orbitofrontal, cingulate and temporal 
cortex. Subcortical ROIs, including the ventral striatum, caudate, putamen, thalamus, 
hypothalamus, dorsal and ventral raphe, were manually delineated on subject’s FGATIR MR 
images using Analyze version 12 (Mayo Foundation) medical imaging software package 
following published guidelines [22]. PDE4 levels were also quantified in additional brain 
regions, defined using the CIC atlas v2.0, not involved in regulating the sleep-wake cycle, 
please see supplemental materials Table S1.  
Connectivity-based parcellations according to cortico-striatal projections 
Diffusion data analysis was performed using FSL Diffusion Toolbox (FDT) (FMRIB Centre 
Software Library, Oxford University). Each phase encoding direction image set, blip-up and 
blip-down, was corrected for motion and eddy current-related distortions. FDT software was 
used to perform probabilistic tractography on each subjects’ diffusion data to parcellate the 
striatum according projections to cortical limbic regions [23, 24]. Methods were following as 
previously described [23, 24]. For each striatal voxel 10,000 sample tracts were generated to 
enable estimates of striatal connectivity profile with each target. The cortical-striatal 
connectivity maps were thresholded at 5% of the maximum connectivity value to minimise 
noise and voxels with low connectivity values, allowing functional subdivisions to have a 
certain degree of overlap. The resulting output connectivity maps for functional subdivisions 
of the striatum according to connectivity to limbic cortical areas were transformed to subjects’ 
structural T1 space. Output connectivity maps were applied to parametric [11C]rolipram VT 
images to calculate regional estimates of VT. The topography of the limbic striatum according 
to connectivity to the cortical limbic regions is illustrated in Figure 1.  
Statistical analysis 
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Statistical analysis and graph illustration were performed with SPSS (version 20 Chicago, 
Illinois, USA) and GraphPad Prism (version 6.0) respectively. For all variables, variance 
homogeneity and normality were tested with Bartlett and Kolmogorov-Smirnov tests. 
Independent t-test (parametric variables) and Mann-Whitney U test (non-parametric variables) 
were used for between-group comparisons, as appropriate, and P values were calculated 
following Bonferroni’s multiple comparisons accounting for the number of regions in allo-
cortical and subcortical groups. Analysis of covariance (ANCOVA) was used to covariate for 
age, disease duration, motor symptom severity, LEDDA, LEDL-DOPA, depression and cognitive 
status in between groups comparisons.  We interrogated correlations between PET and clinical 
data using Spearman’s r correlation coefficient and applied Benjamini-Hochberg correction 
with the false discovery rate cut-off at 0.05. Correlations were repeated including age, disease 
duration, motor symptom severity, LEDDA, LEDL-DOPA, depression and cognitive status as 
covariate. All data are presented as mean±SD, and the level α was set for all comparisons at 
P<0.05, Benjamini-Hochberg corrected. 
 
Results  
No differences were found in clinical measures including age (P>0.10), disease duration 
(P>0.10), motor symptoms severity (P>0.10), daily intake of total levodopa equivalent units 
(LEDTotal; P>0.10), daily LEDDA (P>0.10) or daily LEDL-DOPA (P>0.10), depressive symptoms 
[BDI-II (P>0.10), HAM-D (P>0.10)] and cognitive function [MMSE (P>0.10); MoCA 
(P>0.10)] between the group of PD patients with and without EDS (Table 1).  
PD patients with EDS had significantly increased [11C]rolipram VT compared to patients 
without EDS but not compared to healthy controls (Figure 2B). Specifically, [11C]rolipram VT 
was significantly increased in PD patients with EDS in the caudate (P=0.029), hypothalamus 
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(P=0.013), hippocampus (P=0.036) and limbic striatum (P=0.030) compared to PD without 
EDS (Figure 2A, Table 2). The results remained consistent after covariation for age, disease 
duration, motor symptom severity, LEDDA, LEDL-DOPA depression and cognitive status. MRI 
volumetric analysis confirmed no significant differences in ROIs volume between groups 
(P>0.05) (Table 3). 
To support findings that PDE4 levels are elevated in brain regions regulating the sleep-wake 
cycle, we also quantified PDE4 levels in additional brain regions not involved in sleep 
regulation. We found no differences in frontal, occipital, temporal and parietal regions between 
PD patients with and without EDS (Table S1).   
Higher ESS scores were associated with increased [11C]rolipram VT in the caudate (r=0.77; 
P=0.003), hypothalamus (r=0.84; P=0.001), hippocampus (r=0.81; P=0.001) and limbic 
subdivisions of the striatum (r=0.80; P=0.003) (Figure 2C). These results were confirmed after 
controlling for age, disease duration, motor symptom severity, LEDDA, LEDL-DOPA depression 
and cognitive status.  
 
Discussion  
Our findings suggest that EDS in PD is associated with increased PDE4 expression in brain 
regions involved in the regulation of sleep and wakefulness. We used a region-of-interest based 
approach, combining anatomical and DTI connectivity-based analysis, to assess PDE4 
expression in the caudate, hypothalamus, hippocampus and limbic subdivisions of the striatum. 
Our findings translate to humans, preclinical data, which have demonstrated that elevated 
levels of PDE4 expression are involved in the pathophysiology of EDS [7, 9, 10]. 
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Recently, loss of PDE4 expression has been reported in PD patients compared to healthy 
controls, with decreased PDE4 associated with deficits in spatial working memory [13]. Here, 
we report relative increased PDE4 expression associated with severity of EDS in limbic brain 
regions. Elevated PDE4, in specific brain regions involved in sleep regulation, occurs only in 
PD with EDS and is evident when comparing similar disease stage and cognitive status PD 
patients without EDS but not when compared to healthy controls. In PD with EDS, relative 
increases in PDE4 might mask PD-related loss of PDE4 and conversely, increased PDE4 levels 
might be underestimated due to parallel loss of PDE4. It could be argued that substantial 
increased PDE4 expression would have to occur in order to counter the PD-related loss of 
PDE4, and is necessary for development of EDS. Further studies in larger cohorts are warranted 
to elucidate the relationship between overall PD-related loss of PDE4 and regional increased 
in PDE4 associated with EDS.  
The hypothalamus is a critical area involved in modulating the sleep-wake cycle; the 
ventrolateral preoptic nucleus acts to inhibit major arousal mechanisms, thus promoting sleep 
[25]. Recently, the severity of EDS in PD was shown to be associated with reduced 
hypothalamic post-synaptic dopamine type-3 receptor (D3R) availability [5], as well as striatal 
dopaminergic dysfunction [4]. PDE4 regulates cAMP/PKA signalling at dopaminergic 
terminals subsequently modulating dopamine activity [11]. Therefore, by modulating 
dopamine release, elevated PDE4 levels in dopaminergic innervating neurons to the 
hypothalamus and striatum could influence dopamine receptor availability contributing to 
mechanisms underlying EDS. In vitro and animal studies showed that rolipram, a PDE4 
inhibitor, can increase dopaminergic tone in the striatum by stimulating dopamine synthesis 
and decreasing striatal D2R signalling [11, 26]. Therefore, elevated PDE4 could promote 
daytime sleepiness via modulating striatal dopaminergic tone and dopamine receptor signalling 
[27, 28]. Furthermore, elevated PDE4 levels in PD with EDS could exacerbate striatal 
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dopaminergic degeneration by decreasing CREB phosphorylation [29, 30]. A recent preclinical 
study demonstrated that elevated cAMP/PKA signalling is linked to sleep dysfunction [8]. 
Further studies are required to understand if increases in PDE4 expression are a compensatory 
mechanism to counteract earlier increase in cAMP/PKA signalling, or if elevated PDE4 is a 
primary pathological process underlying sleep dysfunction in PD.  
DTI connectivity-based analysis revealed increases in PDE4 expression within limbic 
subdivisions of the striatum, which was associated with the severity of daytime sleepiness. 
During sleep the limbic system is thought to act to integrate emotions and memory, and 
consolidating memories [31]. Behavioural changes due to sleep deprivation, such as cognitive 
deficits and mood changes [32], have been linked to increased PDE4 expression and altered 
cAMP signalling [32]. In a preclinical study, sleep deprivation selectively impaired 
cAMP/PKA-dependent forms of synaptic plasticity in the hippocampus, through increased 
activity and protein levels of PDE4 [9]. Treatment with the PDE4 inhibitor rolipram, rescued 
sleep deprivation-induced deficits in cAMP signalling, synaptic plasticity and hippocampus-
dependent memory [9]. Furthermore, a preclinical animal study demonstrated that rolipram 
was able to enhance wakefulness by increasing the availability of cAMP [7]. Here, we suggest 
that relatively increased PDE4 expression occur only in PD patients with EDS. Therefore, 
modulation of PDE4 in PD with EDS, to restore to normal levels, could be a suitable 
pharmacological target to ameliorate daytime sleepiness, as well as behavioural changes related 
to sleep deprivation. However, further studies in larger cohorts of patients and healthy controls 
are required to confirm these results. 
In this study, there were no differences in the dopaminergic medication, LEDDA or LEDL-DOPA, 
between groups of PD patients with and without EDS suggesting that the upregulation of PDE4 
in PD patients with EDS is not driven by dopaminergic medication. However, it is worth 
considering that the absence of association between the use of dopamine agonist and the 
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upregulation of PDE4 does exclude the possibility that dopamine agonists could induce EDS 
and the upregulation of PDE4. Further studies are warranted to fully elucidate the relationship 
between dopamine medication, in particular dopamine agonists, and the upregulation of PDE4 
in association with EDS.  A limitation of the current study is the small sample sizes which 
might reduce statistical power to detect between group differences in clinical variables which 
might influence PDE4 levels. Therefore, while our results remained after controlled for clinical 
variables, we cannot completely exclude the potential influence of other factors on PDE4 
levels. Further studies with larger cohorts of PD patients with and without EDS are required to 
validate our findings.  
In conclusion, we provide preliminary evidence that elevated PDE4 expression is associated 
with the severity of EDS in PD patients. Therefore, altered PDE4 expression could represent a 
possible mechanism underlying the pathophysiology of EDS in PD.  
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Figure legend 
Figure 1: Segmentation of the limbic striatum based on cortical-connectivity. Schematic 
illustration of striatal subdivisions (left) according to cortical-connectivity associated with 
limbic (orange), cognitive (blue) and sensorimotor (green) functional specialisation. 
Probabilistic tractography was used to parcellate the striatum according to projections to the 
limbic cortex to create the limbic striatum (orange). Connectivity maps, of the limbic striatum, 
were produced for subject where each voxel in the striatum is assigned according to the 
probability of connectivity to limbic cortical areas. An output connectivity map for a 
representative healthy control in shown (right) to illustrate topography of the limbic striatum.   
 
Figure 2: Elevated phosphodiesterase 4 (PDE4) in Parkinson’s disease (PD) patients with 
daytime sleepiness. (A) Bar graphs showed increased PDE4 in PD with EDS compared to PD 
without EDS and healthy controls; (B) [11C]rolirpam PET images for a PD patient with EDS 
(80 year old female; disease duration 25 years; ESS=14) and a PD patient without EDS (68 
year old female; disease duration 7 years; ESS=3); (C) Significant positive correlation between 
increased [11C]rolipram VT and higher ESS scores. *P<0.05 Bonferroni corrected for multiple-
comparisons. Abbreviations: PDE4 = Phosphodiesterase 4; PD = Parkinson’s disease; EDS = 
Excessive Daytime Sleepiness; EES = Epworth Sleepiness Scale; VT = Volume of Distribution.  
 
Tables 
Table 1: Clinical characteristics of Parkinson’s disease patients and healthy controls 
 
Healthy 
Controls 
PD without EDS 
ESS <10 
PD with EDS 
ESS ≥10 
No Subjects 6 7 5 
Sex 4 M / 2 F 5 M / 2 F 2 M/ 3 F 
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Age (years ±SD) 64.9 (±3.0) 71.2 (±6.1) 70.8 (±10.0) 
Disease duration (years 
±SD) 
- 9.7 (±4.4) 13.4 (±7.9) 
Daily LEDTotal 
(mg±SD) 
- 1130.0 (±1409.0) 1031.9 (±878.5) 
Daily LEDL-DOPA 
(mg±SD) 
- 1047.9 (±1368.0) 891.9 (±848.6) 
Daily LEDDA (mg±SD) - 82.14 (±80.3) 140.0 (±128.1) 
H&Y (mean ±SD) - 2.6 (±1.0) 2.9 (±1.0) 
UPDRS-III  
(mean ±SD) 
- 34.7 (±15.7) 44.6 (±16.7) 
UPDRS-I total (mean 
±SD) 
2.8 (±3.8) 8.6 (±7.1) 9.5 (±8.1) 
NMSS total  
(mean ±SD) 
6.3 (±8.5) 43.9 (±37.0) 61.6 (±18.2) 
PDSS (mean ±SD) 126.2 (±26.9) 117.0 (±12.7) 88.2 (±27.2)* 
ESS (mean ±SD) 3.3 (±3.3) 5.0 (±2.2) 12.2 (±2.3)*** 
MMSE (mean ±SD) 29.8 (±0.4) 27.7 (±1.6) 28.00 (±2.4) 
MOCA (mean ±SD) 28.2 (±1.6) 27.1 (±2.1) 28.00 (±2.0) 
HAM-D (mean ±SD) 1.3 (±1.2) 4.3 (±3.3) 8.6 (±5.2) 
BDI-II (mean ±SD) 1.8 (±2.5) 6.4 (±3.7) 12.0 (±7.0) 
PDQ-39 (mean ±SD) 0.3 (±0.2) 25.3 (±18.2) 47.2 (±22.1) 
Abbreviations: LEDL-DOPA = Levodopa Equivalent Dose; LEDDA = Dopamine Agonist Equivalent Dose; 
H&Y = Hoehn and Yahr; UPDRS = Unified Parkinson’s Disease Rating Scale; PDQ-39 = 39-item 
Parkinson's Disease Questionnaire; MMSE = Mini Mental State Examination; BDI-II = Beck 
Depression Inventory-II; HAM-D = Hamilton Depression Rating Scale; PDSS = Parkinson’s Disease 
Sleep Scale; EES = Epworth Sleepiness Scale; NMS = Non-Motor Symptoms assessment scale; SD = 
Standard Deviation. UPDRS scores reported in OFF medication state after overnight withdrawal of 
patient’s dopaminergic medication. Comparisons between PD groups with and without EDS: 
***P<0.001; **P<0.05. 
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Table 2: [11C]Rolipram volume of distribution (VT) in groups of Parkinson’s patients with and 
without excessive daytime sleepiness 
 
Healthy 
Controls 
(n=6) 
PD without EDS 
ESS <10 
(n=7) 
PD with EDS 
ESS >10 
(n=5) 
P value 
% changeb 
Caudate 0.70 (±0.15) 0.53 (±0.17) 0.74 (±0.11) 
0.029 
38% 
Putamen 0.86 (±0.15) 0.73 (±0.18) 0.95 (±0.12) >0.05 
Ventral Striatum 0.83 (±0.14) 0.72 (±0.17) 0.93 (±0.10) >0.05 
Thalamus 0.74 (±0.14) 0.57 (±0.16) 0.72 (±0.10) >0.05 
Hypothalamus 0.58 (±0.11) 0.48 (±0.12) 0.66 (±0.06) 
0.013 
37.7% 
Dorsal Raphe 0.60 (±0.11) 0.50 (±0.13) 0.64 (±0.07) >0.05 
Ventral Raphe 0.57 (±0.09) 0.47 (±0.12) 0.62 (±0.07) >0.05 
Amygdala 0.73 (±0.15) 0.58 (±0.16) 0.76 (±0.10) >0.05 
Limbic Striatuma 0.95 (±0.12) 0.69 (±0.19) 0.92 (±0.09) 
0.030 
33.9% 
Hippocampus 0.78 (±0.8) 0.58 (±0.15) 0.76 (±0.07) 
0.036 
30.8% 
Orbitofrontal 
Cortex 
0.84 (±0.13) 0.68 (±0.18) 0.87 (±0.10) >0.05 
Cingulate 0.80 (±0.14) 0.63 (±0.16) 0.83 (±0.10) >0.05 
Temporal Cortex 0.82 (±0.09) 0.61 (±0.16) 0.81 (±0.08) >0.05 
a Limbic Striatum: functional connectivity-based striatal subdivision connecting to cortical limbic 
regions. bP values (Bonferroni corrected) and percentage change for between Parkinson’s disease 
groups with and without excessive daytime sleepiness. Data shown as (mean±SD). Abbreviations: EDS 
= Excessive daytime sleepiness; ESS= Epworth Sleepiness Scale; PD = Parkinson’s disease. 
 
Table 3: MRI volumetric analysis in healthy controls and Parkinson’s disease patients with 
and without excessive daytime sleepiness  
Region 
Healthy 
Controls 
PD without 
EDS 
ESS <10  
PD with EDS 
ESS >10 
P value  
Caudate R  2.20 (±0.07) 2.25 (±0.28) 2.37 (±0.34) >0.05 
Caudate L  2.18 (±0.07) 2.14 (±0.29) 2.33 (±0.26) >0.05 
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Putamen R  3.09 (±0.26) 2.97 (±0.46) 3.17 (±0.11) >0.05 
Putamen L  3.39 (±0.32) 3.22 (±0.55) 3.52 (±0.29) >0.05 
Ventral Striatum R  1.11 (±0.17) 1.21 (±0.21)  0.93 (±0.34) >0.05 
Ventral Striatum L  1.04 (±0.18) 1.10 (±0.20) 0.90 (±0.18) >0.05 
Thalamus R  4.17 (±0.35) 4.04 (±0.38) 4.04 (±0.45) >0.05 
Thalamus L  4.69 (±0.44) 4.66 (±0.68) 4.57 (±0.43) >0.05 
Hypothalamus R 0.14 (±0.06) 0.16 (±0.06) 0.15 (±0.06) >0.05 
Hypothalamus L 0.16 (±0.06) 0.17 (±0.06) 0.14 (±0.04) >0.05 
Dorsal Raphe 0.30 (±0.12) 0.31 (±0.08) 0.31 (±0.06) >0.05 
Ventral Raphe  0.26 (±0.11) 0.28 (±0.10) 0.28 (±0.04) >0.05 
Hippocampus R  2.66 (±0.21) 2.22 (±0.31) 2.48 (±0.21) >0.05 
Hippocampus L  2.52 (±0.15) 2.19 (±0.37) 2.38 (±0.30) >0.05 
Limbic Striatum R 1.96 (±0.62) 1.50 (±0.60) 1.92 (±0.30) >0.05 
Limbic Striatum L 1.67 (±0.61) 1.69 (±0.54) 1.85 (±0.53) >0.05 
Amygdala R  1.03 (±0.11) 0.80 (±0.26) 0.98 (±0.15) >0.05 
Amygdala L 0.97 (±0.10) 0.84 (±0.24) 0.98 (±0.12) >0.05 
Orbitofrontal Cortex R 2.40 (±0.10) 2.39 (±0.13) 2.38 (±0.23) >0.05 
Orbitofrontal Cortex L 2.51 (±0.08) 2.41 (±0.13) 2.44 (±0.15) >0.05 
Cingulate R  2.35 (±0.14) 2.43 (±0.16) 2.27 (±0.32) >0.05 
Cingulate L  2.52 (±0.17) 2.49 (±0.13) 2.67 (±0.17) >0.05 
Temporal Cortex R  3.65 (±0.32) 3.48 (±0.24) 3.44 (±0.60) >0.05 
Temporal Cortex L 3.57 (±0.24) 3.43 (±0.46) 3.44 (±0.13) >0.05 
Data shown as (mean±SD). Abbreviations: PD = Parkinson’s disease; EDS = Excessive Daytime 
Sleepiness; ESS= Epworth Sleepiness Scale. 
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